ArticleFrontiers in public health2025

Comparative cost-effectiveness of sintilimab, toripalimab, and camrelizumab in first-line therapy for advanced non-squamous non-small cell lung cancer.

Jie Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.